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Background: Thallium (Tl) is a toxic heavy metal that exists in nature. Tl poisoning (thallotoxicosis) may occur in
opioid addicts. This study was designed to evaluate the frequency and level of urinary Tl in opioid abusers. In
addition, clinical findings were evaluated.
Methods: A total of 150 subjects were examined. Cases with a history of at least 3 years of abuse were admitted in
the Imam Reza Hospital as the case group; 50 non-opioid abusers from the target population were included as the
control group. Twenty-four hour urinary qualitative and quantitative Tl analyses were performed on both groups.
Results: Out of the 150 subjects, 128 (85 %) were negative for qualitative urinary Tl, followed by 5 % (trace),
7 % (1+), 2 % (2+), and 1 % (3+). Mean (standard error (SE), Min–Max) quantitative urinary Tl level was 14 μg/L (3.5 μg/L,
0–346 μg/L). Mean urinary Tl level in the case group was 21 μg/L (5 μg/L, 0–346 μg/L) and that in the controls was
1 μg/L (0.14 μg/L, 0–26 μg/L), which were significantly different (P = 0.001). The most frequent clinical findings were
ataxia (86 %), sweating (81 %), and constipation (54 %). In all cases (n = 150), the mean (SE) value for cases with positive
qualitative urinary Tl was 26.8 μg/L (0.9 μg/L) and that in the negative cases was 2.3 μg/L (0.2 μg/L), which were
significantly different (P = 0.002).
Conclusions: This study showed that long-term opioid abuse may lead to Tl exposure. In opioid abusers with the
clinical manifestation of thallotoxicosis, urinary Tl should be determined.
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Thallium (Tl) is a highly toxic heavy metal with atomic
number 81 and a molecular weight of 204.37 discovered
by Sir William Crookes in 1861 [1]. It is a soft, bluish-
white or gray water-insoluble metal but the salt forms
are colorless, tasteless, and odorless. Tl is readily
absorbed via ingestion, inhalation, and dermal contact
[1–3]. Tl does not have any biological function in the
body and the fatal dose is more than 10–15 mg/kg of
body weight [4]. In the past, Tl was used as a hair re-
mover and rodenticide because of its toxicity, but pres-
ently Tl administration is restricted to industrial usage
such as optic lenses, and the radioisotope forms are
used for medical purposes such as diagnosis of malig-
nancies (such as melanoma) and tissue scintigraphy
(such as cardiac scanning) [5]. Any amount of Tl in* Correspondence: AfshariR@mums.ac.ir
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creativecommons.org/publicdomain/zero/1.0/the body is abnormal [1]. In humans, Tl toxicity may
occur occupationally (industrial exposure), accidentally
(contact with Tl-containing material), or in cases of homi-
cide; oral ingestion is the main route of Tl entrance in the
body [1]. The clinical manifestation of thallotoxicosis has
a wide spectrum but painful ascending peripheral neur-
opathy (both motor and sensory), gastrointestinal, and
dermatologic manifestations (particularly alopecia) are
major characteristics in Tl toxicity [5]. The exact
mechanism of toxicity is still unclear, but because Tl
ions are similar to potassium (K) ions, Tl may alter
the number of K-dependent systems and enzymes in
the body such as sulfhydryl groups, essential enzymes
in the Krebs cycle, succinate dehydrogenase, and in-
teractions with sodium-potassium ATPase and ribofla-
vin [3, 6, 7]. Treatment includes early gastrointestinal
decontamination, Prussian blue therapy (potassium
ferric hexacyanoferrate), activated charcoal, laxatives,
and enhanced elimination via forced diuresis and
hemodialysis [3, 6, 8]. In Tl poisoning, early diagnosis
and treatment is necessary for complete recovery; anyarticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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Illicit opium may be adulterated with various substances
such as sugars, quinine, caffeine, lactose, strychnine, para-
cetamol, and heavy metals such as lead [10, 11]. In fact,
salesmen and smugglers may add any kind of heavy metals
to opium to increase its weight for more profit. Recently,
there have been reports of Tl toxicity in illicit opium users
[12, 13]. We decided to evaluate Tl as an adulterant in
opioid-like compounds from opium users, for the early
diagnosis and treatment of thallotoxicosis.
Methods
Study design
This is a case–control study. One-hundred opioid-like
abusers, raw opium, opium residue, crystal heroin, or
mixed abusers for more than 3 years, aged 18–65 years,
were recruited following admission to Imam Reza Hospital
because of poisoning or rehabilitation as the case group.
Controls were 50 non-abuser subjects with no history of
drug use in the previous year. Urinary morphine tests using
immunoassay tests were used to determine positive cases.
Controls were verified to be opioid naïve via verbal conver-
sation. All ethical approvals were considered and the aim
of the study was explained to all subjects in both groups.
Twenty-four hour urinary samples were taken on admis-
sion for qualitative and quantitative Tl analyses, and other
data including demographic, neurological, dermal, and
gastrointestinal clinical findings were entered into a prede-
signed checklist. Diphenoxylate, acetaminophen codeine,
and tramadol users were excluded from the study.
Laboratory assessment
In acute poisoning, high concentrations of Tl appear
in the kidney; thus, urine is the fluid of choice for Tl
detection [14]. The normal concentration is <5 μg/L
(<24.5 nmol/L) in a 24-h urine sample. The urine
samples were placed in 100 mL urine collection containers
(polyethylene) and stored at −20 °C until analysis [15].
The first 24-h urinary samples in the two groups were ex-
amined for Tl using a qualitative (semi-quantitative) sur-
vey. Reagents included: 1) cyanide reagent: 1.6 g of
sodium hydroxide, 1.2 g of sodium-potassium tartrate,
and 1.36 g of potassium cyanide dissolved in 10 mL of
water. 2) Dithizone solution (250 mg/L) in chloroform
prepared fresh: 12 mL urine sample and 1 mL cyanide re-
agent to dithizone solution (dithizone + chloroform) were
combined, shaken for 2 min, and left for 3–5 min. Two-
phase formation occurred, consisting of an upper urine
phase and a lower chloroform phase. A pink-red color in
the lower chloroform phase indicates the presence of Tl
and indicates a positive result. According to semi-
quantitative Tl-screening tests, <50 μg/L is considered
negative, trace (50–100 μg/L), 1+ (100–200 μg/L), 2+
(200–300 μg/L), 3+ (300–400 μg/L), and 4+ (>400 μg/L)[16]. In the second step, quantitative analysis via graphite
furnace atomic absorption spectrometry (Perkin Elmer,
Model 3030 with HGA 400 Programmer), which is a
highly sensitive spectroscopic technique that provides ex-
cellent detection limits for measuring concentrations of Tl
in urine, was performed on all samples [17]. In this test,
we applied a Tl standard solution, traceable to standard
reference materials from National Institute of Standards
and Technology thallium(I) nitrate in nitric acid 0.5 mol/L
(1000 mg/L) TlCertipur®, provided from Merck. To meas-
ure TL in urine, after extraction with nitric acid, sulfuric
acid, and Triton X- 100, the liquid phases were separated
from the sediment. Next, 2 % ammonium monovanadate
in 1 % sodium hydroxide was then added to neutralize
acidity to prevent graphite tube damage. The solution was
centrifuged at high speed for 5 min, and 25 μL from the
upper layer was injected into the graphite. A thermal pro-
gram was selected for drying; 130 °C, 300 °C for organic
solvents, and 800 °C for inorganic solvents and ash re-
moval, and 1700 °C for atomization. Absorbance was mea-
sured at 276.8 nm [18, 19]. Detection limits were 0.2 μg/L,
precision 3.65 %, and accuracy 97.4 % of analyses were de-
termined by repeated analyses of biological reference ma-
terial (SERONORM urine trace element level 2, lot
1011645) [20]. We evaluated both qualitative and quanti-
tative urinary Tl because they complement each other.
Statistical analysis
Data were analyzed with SPSS software (version 16). Stu-
dent’s t test and Spearman’s coefficient test were used to
analyze the data. P value was considered to be less than
0.05 throughout the study.
Results
Demographic findings
In total, 150 subjects, including 100 cases and 50 con-
trols, were recruited. Among them, 134 (89 %) were
male. Mean (standard error (SE), Min–Max) age was 41
(1.2, 19–85) years. Mean (SE) age in cases was 41 years
(1.6) and in controls was 41 years (0.3), which were simi-
lar. Among cases, raw opium or opium residues were
used by 66 % cases, followed by mixed (28 %), and
crystal heroin (6 %). Cases only smoking were 49 %,
those smoking and ingesting were 45 %, those only
injecting were 3 %, and those using a mixture of
methods were 3 %.
Clinical findings
Neurological
Frequency of ataxia in cases (n = 100) was 86 %, followed
by tremor (85 %), insomnia (83 %), depression (82 %),
blurred vision (79 %), memory deficits (78 %), weakness
(77 %), fatigue (77 %), aggressiveness (77 %), jerking
movements (76 %), vertigo (73 %), emotional liability
Table 1 Qualitative urinary thallium results (n = 150)
Qualitative Urinary
Thallium Results
Cases n (%) Controls n (%) Total n (%)
Negative 80 (80) 48 (96) 128 (85)
Trace 6 (6) 1 (2) 7 (5)
1+ 10 (10) 1 (2) 11 (7)
2+ 3 (3) 0 (0) 3 (2)
3+ 1 (1) 0 (0) 1 (1)
Total 100 (100) 50 (100) 150 (100)
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(38 %), seizure (36 %), delirium-psychosis-coma (30 %),
and choreoathetosis (0 %).
Dermal: Frequency of sweating in cases (n = 100) was
81 %, followed by scalp hair loss (45 %), dry skin (36 %),
acne (8 %), rashes (6 %), body hair loss (5 %), Mees’ lines
(0 %), and palmar erythema (0 %).
Gastrointestinal: Frequency of constipation in cases
(n = 100) was 54 %, followed by nausea (20 %), vomit-
ing (20 %), abdominal pain (16 %), and diarrhea
(14 %).
Qualitative urinary Tl results
For all subjects, 128 (85 %) were negative for qualitative
urinary Tl, followed by 5 % (trace), 7 % (1+), 2 % (2+),
and 1 % (3+). The distribution of qualitative results is
shown in Table 1. The two groups were significantly dif-
ferent (P = 0.01).
Quantitative urinary Tl level
The mean (SE, Min–Max) quantitative urinary Tl level was
14 μg/L (3.5 μg/L, 0–346 μg/L). Mean urinary Tl levels in
the case group were 21 μg/L (5 μg/L, 0–346 μg/L) and in
controls were 1 μg/L (0.14 μg/L, 0–26 μg/L), which were
significantly different (P = 0.001).
Comparison of qualitative and quantitative results
In all cases (n = 150), the mean (SE) value for cases with
positive qualitative urinary Tl levels was 26.8 μg/L (1 μg/L)
and in negative cases was 2.3 μg/L (0.4 μg/L), which were
significantly different (P = 0.002).
Duration of abuse was not associated with Tl levels
(r = 0.329, P = 0.099). Positive Tl results were signifi-





(Crystal) Heroin 5(83 %) 0(0 %) 1(16 %)
Opium 51(77 %) 5(7 %) 7(10 %)
Mixed user 24(85 %) 1(3 %) 2(7 %)
Total 80(80 %) 6(6 %) 10(10 %)with heroin abusers (P < 0.001). Table 2 summarizes
these differences. Positive Tl results were significantly
higher for smoke and ingestion compared with ingestion
alone (P = 0.001). Table 2 summarizes these differences.
Discussion
Our results indicate that contaminated opiates could be
a source of Tl poisoning. Substance abuse is one of the
most preventable health hazards worldwide. Iran appears
to have both traditional and modern drug use and abuse
problems, and it appears to play an important transit
role in the transfer of opium and other drugs from
Afghanistan to western countries [21, 22]. Adding heavy
metals such as lead adulterant to the drugs is already de-
scribed [23, 24]. Opium is still a most frequently abused
drug. Informal, and often illegal, laboratories refine
opium into a sticky, brown paste, which is pressed into
bricks and sun dried. This material can then be ingested
or smoked. This process results in introduction of im-
purities such as lead into the product [25]. Salesmen and
smugglers may add any number of heavy metals to
opium to increase the weight for more profit. Although
the amount of Tl in opium is usually small, when taken
in large amounts, opium adulterated with Tl can pro-
duce clinical toxicity. However, very few reports describe
unusual and exotic causes of chronic Tl poisoning as an
adulterant to illicit drugs [12–14]. Afshari et al. reported
three cases of suspected Tl poisoning after heroin abuse.
Urine qualitative tests resulted in a range from negative
to 4+ Tl, and three months after substitution of heroin,
signs and symptoms of thallotoxicos returned; they con-
cluded that contaminated heroin was responsible [13].
Questel et al. also reported two cases of Tl poisoning in
heroin users [12].
In our study, the most frequent symptoms were ataxia,
tremor, insomnia, neuropathy (both sensory and motor),
sweating, scalp hair loss, dry skin, constipation, nausea,
and vomiting, which were slightly different from previ-
ous studies that emphasized on polyneuropathy, paresis,
abdominal pain, and alopecia [4, 6, 9, 21]. This dissimi-
larity may be because of the amount of Tl used or less
severity of toxicity. There were significant differences in
urinary Tl tests between case and control groups in
addition to clinical findings. Surprisingly, nearly one-
third of our patients had a history of seizure, possiblyt type of abused drugs (n = 100)
Total
2+ 3+ Positive
0(0 %) 0(0 %) 1(16 %) 6(100 %)
2(3 %) 1(1 %) 15(21 %) 66(100 %)
1(3 %) 0(0 %) 4(13 %) 28(100 %)
3(3 %) 1(1 %) 20(20 %) 100(100 %)
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of illicit drugs. In Iran, opium addicts have a great affin-
ity for tramadol because of the euphoria experience or
because of replacement of opiates [26–27]. Our study
showed the most frequent illicit substance was raw
opium and opium residue (66 %), and positive Tl results
were significantly higher in this group in comparison
with other abusers. In addition, ingestion and smoking
was the most frequent route of consumption in the posi-
tive Tl group. Comparison between qualitative and quanti-
tative results indicated that for exact diagnosis, it is better
to incorporate both qualitative and quantitative analyses.
Tl poisoning has a wide spectrum of clinical manifestation
and any amount of Tl in the human body is abnormal.
Moreover, it acts as a silent disease and diagnosis is some-
times difficult without suspicion. Our study showed that
opium is a source of Tl in Iran and maybe in other parts
of the world, so physicians should be aware of Tl exposure
in opioid abusers, and they should be notified of its clin-
ical symptoms. Although our findings suggested chronic
Tl poisoning as an adulterant to illicit drugs, it should be
noted that the findings may also result from cultivating
opium poppies in Tl-contaminated soils or water.
Conclusion
As Tl is an accumulative poison [9], any illicit abuser sub-
ject with neuropathy, gastrointestinal complaints, and alo-
pecia should be suspected of thallotoxicosis, and both
urinary qualitative and quantitative Tl analyses would be
helpful for exact diagnosis.
Limitations
This study is subjected to certain limitations because of
the incontinency of opioid concentration and dose in
the street drug abusers.
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